Summary
Biofrontera AG (B8FK) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Biofrontera AG ever had a stock split?
Biofrontera AG Profile
| Specialty Retail Industry | Consumer Discretionary Sector | Ms. Pilar de la Huerta Martinez CEO | XETRA Exchange | - ISIN |
| Germany Country | 79 Employees | - Last Dividend | 14 May 2024 Last Split | - IPO Date |
Overview
Biofrontera AG is a biopharmaceutical company that is focused on the research, development, and commercialization of dermatological products. Established in 1997, the company has carved out a niche in the dermatology sector by bringing innovative solutions to the market, particularly for the treatment of skin conditions such as actinic keratoses, field cancerization, and squamous cell carcinoma. Biofrontera AG has established a strategic collaboration and partnership with Maruho Co., Ltd., enhancing its reach and development capabilities. Headquartered in Leverkusen, Germany, the company continues to focus on addressing unmet medical needs in dermatology.
Products and Services
- Ameluz
- BF-RhodoLED Lamp
- RhodoLED XL
- Belixos
Ameluz is a treatment developed by Biofrontera AG for mild and moderate actinic keratoses on the face and scalp. Actinic keratoses are rough, scaly patches on the skin, caused by years of sun exposure, which can potentially lead to skin cancer if left untreated. Ameluz is used in photodynamic therapy (PDT), a process that involves applying the medication to the lesions and then exposing them to a light source, leading to the destruction of the affected cells.
The BF-RhodoLED lamp is specifically designed to work in conjunction with Ameluz for the effective treatment of actinic keratoses through photodynamic therapy (PDT). This state-of-the-art lamp emits light at a precise wavelength, activating the applied drug and facilitating the targeted destruction of precancerous cells without harming the surrounding healthy skin.
RhodoLED XL represents an advancement in the treatment of actinic keratoses, particularly designed for patients with multiple interspersed lesions. This larger version of the BF-RhodoLED lamp allows for the treatment of broader areas, making the PDT process more efficient and convenient for patients with extensive skin damage due to sun exposure.
Belixos is a part of Biofrontera AG’s medical skin care range, specifically formulated for irritated and sensitive skin. This product line leverages the power of natural ingredients and scientific research to provide soothing relief and effective care for a variety of skin problems. Belixos products aim to calm, repair, and protect the skin, offering a gentle yet effective option for daily skincare.
Contact Information
